Medical Device Purchases In China To Require Expert Approval
This article was originally published in PharmAsia News
The Ministry of Health in China revealed that due to the large upfront investment and operational costs which will increase medical fees, big medical equipment and facilities will need expert evaluation and approval before they can be purchased and operated. The ministry requires hospitals and medical organizations installing devices exceeding 5 million yuan ($696,475 )to provide the price breakdown, treatment fees, cost analysis and other details. After giving temporary approval of one to two years, the experts will further assess the safety and effectiveness of the equipment before deciding on granting full approval. The ruling will affect large medical implementations such as PET, gamma ray stereotactic radiotherapy system (Gamma Knife), medical cyclotron, and proton therapy system. (Click here for more - Chinese Language)
You may also be interested in...
Funds will be used to expand European sales of the CE-marked Lenire device, scale-up manufacturing and progress US regulatory and reimbursement plans.
RB CEO Laxman Narasimhan sees the potential for the company to establish a global supplements business built on the successes it has enjoyed in the US and China. The comments came as RB reported solid growth in the third quarter, despite struggles for its OTC brands.
Increases in remote patient monitoring and decentralized clinical trials – accelerated by COVID-19 – have added complexity to data management systems. Traditional platforms and electronic data capture used by drug development sponsors are ineffectual tools for integrating new primary data sources, or managing remote patient monitoring, Raj Indupuri, CEO at eClinical Solutions told In Vivo.